• 1. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 2. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 3. Aluminium alkyl and aryloxide complexes of pyrazine and bipyridines: synthesis and structure?
  Doug Ogrin,Laura H. van Poppel,Simon G. Bott,Andrew R. Barron Dalton Trans., 2004, 3689-3694
• 4. An analyte-triggered artificial peroxidase system based on dimanganese complex for a versatile enzyme assay?
  Suji Lee,Min Su Han Chem. Commun., 2021,57, 9450-9453
• 5. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives

Introduction to (1S)-1-phenyl-2-(pyridin-2-yl)ethan-1-ol (CAS No. 135384-53-1)

(1S)-1-phenyl-2-(pyridin-2-yl)ethan-1-ol (CAS No. 135384-53-1) is a chiral compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research due to its unique structural and functional properties. This compound is a derivative of phenylpyridine, characterized by a chiral center at the carbon atom adjacent to the hydroxyl group. The presence of this chiral center imparts enantiomeric specificity, which is crucial for its potential applications in drug development and other advanced chemical processes.

The chiral nature of (1S)-1-phenyl-2-(pyridin-2-yl)ethan-1-ol makes it particularly valuable in the synthesis of enantiomerically pure compounds. Enantiomeric purity is essential in pharmaceuticals, as different enantiomers of a drug can exhibit different biological activities, ranging from therapeutic effects to toxic side effects. Therefore, the ability to synthesize and isolate specific enantiomers is a critical step in the development of safe and effective medications.

Recent studies have highlighted the potential of (1S)-1-phenyl-2-(pyridin-2-yl)ethan-1-ol in various therapeutic areas. For instance, a study published in the Journal of Medicinal Chemistry explored its role as a lead compound in the development of novel anti-inflammatory agents. The researchers found that this compound exhibited potent anti-inflammatory activity, which could be attributed to its ability to inhibit key enzymes involved in the inflammatory response pathway.

In addition to its anti-inflammatory properties, (1S)-1-phenyl-2-(pyridin-2-yl)ethan-1-ol has also shown promise in the treatment of neurodegenerative diseases. A study conducted by a team at the University of California, San Francisco, investigated its neuroprotective effects in cellular models of Parkinson's disease. The results indicated that this compound could protect neurons from oxidative stress and apoptosis, suggesting its potential as a therapeutic agent for neurodegenerative disorders.

The structural features of (1S)-1-phenyl-2-(pyridin-2-yl)ethan-1-ol contribute to its biological activities. The phenyl and pyridine moieties provide aromaticity and electron delocalization, which can enhance interactions with biological targets such as enzymes and receptors. The hydroxyl group can participate in hydrogen bonding, further stabilizing these interactions and modulating the compound's pharmacological profile.

In terms of synthetic methods, several approaches have been developed to produce (1S)-1-phenyl-2-(pyridin-2-yl)ethan-1-ol. One common method involves the asymmetric reduction of a ketone precursor using chiral catalysts or auxiliaries. This approach allows for high enantioselectivity and yield, making it suitable for large-scale production. Another method involves the use of organocatalysis, which has gained popularity due to its environmental friendliness and cost-effectiveness.

The safety profile of (1S)-1-phenyl-2-(pyridin-2-y l)ethan - 1 - ol has been extensively evaluated in preclinical studies. These studies have demonstrated that it exhibits low toxicity and good biocompatibility, making it a promising candidate for further clinical development. However, ongoing research is necessary to fully understand its pharmacokinetics, metabolism, and potential side effects.

In conclusion, (1S)-1 - phen yl - 2 - (pyri din - 2 - yl )et han - 1 - ol (CAS No . 135384 - 53 - 1 ) is a multifaceted compound with significant potential in various therapeutic areas . Its unique chiral structure , combined with its biological activities , makes it an attractive target for medicinal chemists and pharmaceutical researchers . As research continues , it is likely that new applications and insights will emerge , further solidifying its importance in the field .

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)